Advertisement

Der Hautarzt

, Volume 67, Issue 3, pp 249–264 | Cite as

Therapie der Vitiligo

  • M. MeurerEmail author
  • M. Schild
CME Zertifizierte Fortbildung

Zusammenfassung

Das Spektrum der Therapiemöglichkeiten bei Vitiligo hat sich in den letzten 10 Jahren deutlich erweitert, und wir können unseren Patienten, gestützt durch europäische Leitlinien und Konsensusfindung, wirksamere Behandlungsstrategien anbieten. Die topische Therapie und die UV-Therapie sind die wichtigsten Komponenten der Vitiligobehandlung, die häufig kombiniert werden. Die wichtigsten Zielparameter sind Ausmaß und Dauer der Repigmentierung, das Anhalten der Progression, Vermeidung von Nebenwirkungen und die Besserung der Lebensqualität. Die Wirksamkeit der derzeit verfügbaren Behandlungen ist oft nicht ausreichend. Neue Optionen umfassen antioxidative und melanozytenstimulierende Adjuvanstherapien meist in Kombination mit UV- oder Laserlicht sowie eine topische Erhaltungstherapie zur Rezidivprophylaxe. In vielen Fällen ist eine begleitende psychologische Betreuung sinnvoll.

Schlüsselwörter

Topische Therapie Lasertherapie Glukokortikosteroide Progression Lebensqualität 

Treatment of vitiligo

Abstract

The range of treatment options for vitiligo has significantly expanded in the last 10 years and we can offer our patients more effective treatment strategies supported by European guidelines and consensus findings. Topical and UV therapy are—often in combination—the main components of vitiligo treatment. The main outcome parameters include extent and maintenance of gained repigmentation, cessation of spreading, avoidance of side effects and the influence of the treatment on the quality of life. The efficacy of the currently available treatments is often limited. New options include antioxidative or melanocyte-stimulating adjuvant therapies in combination with UV or laser light as well as a topical maintenance treatment to reduce the risk of recurrences. In many cases, psychological support is indicated.

Keywords

Topical treatment Laser therapy Glucocorticoids Progression Quality of life 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

M. Schild und M. Meurer geben an, dass kein Interessenkonflikt besteht

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Taïeb A, Picardo M, VETF Members (2007) The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 20:27–35CrossRefPubMedGoogle Scholar
  2. 2.
    Sangma LN, Nath J, Bhagabati D (2015) Quality of life and psychological morbidity in vitiligo patients: a study in a teaching hospital from north-East India. Indian J Dermatol 60:142–146CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Porter JR, Beuf AH, Lerner AB, Nordlund JJ (1990) The effect of vitiligo on sexual relationships. J Am Acad Dermatol 22:221–222CrossRefPubMedGoogle Scholar
  4. 4.
    Eleftheriadou V, Thomas K, van Geel N, Hamzavi I, Lim H, Suzuki T, Katayama I, Anbar T, Abdallah M, Benzekri L, Gauthier Y, Harris J, Silva de Castro CC, Pandya A, Goh BK, Lan CC, Oiso N, Al Issa A, Esmat S, Le Poole C, Lee AY, Parsad D, Taïeb A, Picardo M, Ezzedine K (2015) Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus. Pigment Cell Melanoma Res 28:363–369CrossRefPubMedGoogle Scholar
  5. 5.
    Taïeb A, Alomar A, Böhm M, Dell’Anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M (2013) Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol 168:5–19CrossRefPubMedGoogle Scholar
  6. 6.
    Meredith F, Abbott R (2013) Vitiligo: an evidence-based update. Report of the 13th Evidence Based Update Meeting, 23 May 2013, Loughborough, U.K. Br J Dermatol 170:565–570CrossRefGoogle Scholar
  7. 7.
    Ezzedine K, Eleftheriadou V, Whitton M, van Geel N (2015) Vitiligo. Lancet 386:74–84CrossRefPubMedGoogle Scholar
  8. 8.
    Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U (2006) Interventions for vitiligo. Cochrane Database Syst Rev 25:CD003263Google Scholar
  9. 9.
    Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, González U (2010) Interventions for vitiligo. Cochrane Database Syst Rev 20:CD003263Google Scholar
  10. 10.
    Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, González U, Jiyad Z, Eleftheriadou V, Ezzedine K (2015) Interventions for vitiligo. Cochrane Database Syst Rev 2:CD003263PubMedGoogle Scholar
  11. 11.
    Schild M, Meurer M (2016) Vitiligo: Klinik und Pathogenese. Hautarzt 67: 173-188Google Scholar
  12. 12.
    Lilly E, Lu PD, Borovicka JH, Victorson D, Kwasny MJ, West DP, Kundu RV (2013) Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol 69:e11–e18CrossRefPubMedGoogle Scholar
  13. 13.
    Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H (2004) Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol 140:677–683CrossRefPubMedGoogle Scholar
  14. 14.
    Taïeb A, Picardo M (2009) Clinical practice. Vitiligo. N Engl J Med 360:160–169CrossRefPubMedGoogle Scholar
  15. 15.
    Hamzavi IH, Lim HW, Syed ZU (2012) Ultraviolet-based therapy for vitiligo: what’s new? Indian J Dermatol Venereol Leprol 78:42–48CrossRefPubMedGoogle Scholar
  16. 16.
    Van Geel N, Speeckaert R, De Wolf J, Bracke S, Chevolet I, Brochez L, Lambert J (2012) Clinical significance of Koebner phenomenon in vitiligo. Br J Dermatol 167:1017–1024CrossRefPubMedGoogle Scholar
  17. 17.
    Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM (1998) Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol 134:1532–1540PubMedGoogle Scholar
  18. 18.
    Smith DA, Tofte SJ, Hanifin JM (2002) Repigmentation of vitiligo with topical tacrolimus. Dermatology 205:301–303CrossRefPubMedGoogle Scholar
  19. 19.
    Sendur N, Karaman G, Saniç N, Savk E (2006) Topical pimecrolimus: a new horizon for vitiligo treatment? J Dermatolog Treat 17:338–342CrossRefPubMedGoogle Scholar
  20. 20.
    Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Junger M, Bräutigam M (2002) Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 205:271–277CrossRefPubMedGoogle Scholar
  21. 21.
    Lee KY, Jeon SY, Hong JW, Choi KW, Lee CY, Choi SJ, Kim JH, Song KH, Kim KH (2013) Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-α-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: a proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment. J Eur Acad Dermatol Venereol 27:609–616CrossRefPubMedGoogle Scholar
  22. 22.
    Lan CC, Chen GS, Chiou MH, Wu CS, Chang CH, Yu HS (2005) FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 153:498–505CrossRefPubMedGoogle Scholar
  23. 23.
    Korobko IV (2012) Review of current clinical studies of vitiligo treatments. Dermatol Ther 25:17–27CrossRefGoogle Scholar
  24. 24.
    Köse O, Arca E, Kurumlu Z (2010) Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J Dermatolog Treat 21:133–139CrossRefPubMedGoogle Scholar
  25. 25.
    Kathuria S, Khaitan BK, Ramam M, Sharma VK (2012) Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1 % tacrolimus ointment vs 0.05 % fluticasone propionate cream. Indian J Dermatol Venereol Leprol 78:68–73CrossRefPubMedGoogle Scholar
  26. 26.
    Aschoff R, Schwanebeck U, Bräutigam M, Meurer M (2009) Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1 % in patients with mild-to-moderate atopic dermatitis. Exp Dermatol 18:24–29CrossRefPubMedGoogle Scholar
  27. 27.
    Czarnecka-Operacz M, Jenerowicz D (2012) Topical calcineurin inhibitors in the treatment of atopic dermatitis – an update on safety issues. J Dtsch Dermatol Ges 10:167–172PubMedGoogle Scholar
  28. 28.
    Wazir SM, Paracha MM, Khan SU (2010) Efficacy and safety of topical mometasone furoate 0.01 % vs. tacrolimus 0.03 % and mometasone furoate 0.01 % in vitiligo. J Pak Assoc Dermatol 20:89–92Google Scholar
  29. 29.
    Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Braeutigam M; CASM-DE-01 Study Group (2004) Long-term efficacy and safety of pimecrolimus cream 1 % in adults with moderate atopic dermatitis. Dermatology 208:365–372CrossRefPubMedGoogle Scholar
  30. 30.
    Yones SS, Palmer RA, Garibaldinos TM, Hawk JL (2007) Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy. Arch Dermatol 143:578–584CrossRefPubMedGoogle Scholar
  31. 31.
    Cavalié M, Ezzedine K, Fontas E, Montaudié H, Castela E, Bahadoran P, Taïeb A, Lacour JP, Passeron T (2015) Maintenance therapy of adult vitiligo with 0.1 % tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol 135:970–974CrossRefPubMedGoogle Scholar
  32. 32.
    Kapoor R, Phiske MM, Jerajani HR (2009) Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br J Dermatol 160:861–863CrossRefPubMedGoogle Scholar
  33. 33.
    Hossani-Madani AR, Halder RM (2010) Topical treatment and combination approaches for vitiligo: new insights, new developments. G Ital Dermatol Venereol 145:57–78PubMedGoogle Scholar
  34. 34.
    Birlea SA, Costin GE, Norris DA (2008) Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets 9:345–359CrossRefPubMedGoogle Scholar
  35. 35.
    Haass NK, Herlyn M (2005) Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 10:153–163CrossRefPubMedGoogle Scholar
  36. 36.
    Picardo M (2010) In: Picardo M, Taïeb A (Hrsg) Vitiligo. Springer-Verlag, Berlin, S 339–342Google Scholar
  37. 37.
    Chiavérini C, Passeron T, Ortonne JP (2002) Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 16:137–138CrossRefPubMedGoogle Scholar
  38. 38.
    Kumaran MS, Kaur I, Kumar B (2006) Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 20:269–273CrossRefPubMedGoogle Scholar
  39. 39.
    Schallreuter KU, Moore J, Wood JM, Beazley WD, Gaze DC, Tobin DJ, Marshall HS, Panske A, Panzig E, Hibberts NA (1999) In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc 4:91–96CrossRefPubMedGoogle Scholar
  40. 40.
    Gibbons NC, Wood JM, Rokos H, Schallreuter KU (2006) Computer simulation of native epidermal enzyme structures in the presence and absence of hydrogen peroxide (H2O2): potential and pitfalls. J Invest Dermatol 126:2576–2582CrossRefPubMedGoogle Scholar
  41. 41.
    Schallreuter KU, Wood JM, Lemke KR, Levenig C (1995) Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 190:223–229CrossRefPubMedGoogle Scholar
  42. 42.
    Schallreuter KU, Salem MM (2010) Vitiligo. What is new? Hautarzt 61:578–585CrossRefPubMedGoogle Scholar
  43. 43.
    Bakis-Petsoglou S, Le Guay JL, Wittal R (2009) A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol 161:910–917CrossRefPubMedGoogle Scholar
  44. 44.
    Naini FF, Shooshtari AV, Ebrahimi B, Molaei R (2012) The effect of pseudocatalase/superoxide dismutase in the treatment of vitiligo: a pilot study. J Res Pharm Pract 1:77–80CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Galarza C, Ramos W, Gutierrez EL, Oré R, Chía H, Ávila J, Tello M, Ronceros G, Uribe M, Gámez D, Ortega-Loayza AG (2009) Efficacy and security of topical antioxidant therapy versus placebo in the treatment of vitiligo of recent onset. Dermatología Peruana 19:198–204Google Scholar
  46. 46.
    Schallreuter KU (2013) Q10-triggered facial vitiligo. Br J Dermatol 169:1333–1336CrossRefPubMedGoogle Scholar
  47. 47.
    Wu CS, Lan CC, Wang LF, Chen GS, Wu CS, Yu HS (2007) Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo. Br J Dermatol 156:122–129CrossRefPubMedGoogle Scholar
  48. 48.
    Goldstein NB, Koster MI, Hoaglin LG, Spoelstra NS, Kechris KJ, Robinson SE, Robinson WA, Roop DR, Norris DA, Birlea SA (2015) Narrow band ultraviolet B treatment for human vitiligo is associated with proliferation, migration, and differentiation of melanocyte precursors. J Invest Dermatol 135:2068–2076CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Jamal S, Schneider RJ (2002) UV-induction of keratinocyte endothelin-1 downregulates E-cadherin in melanocytes and melanoma cells. J Clin Invest 110:443–452CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Wu CS, Yu CL, Wu CS, Lan CC, Yu HS (2004) Narrow-band ultraviolet-B stimulates proliferation and migration of cultured melanocytes. Exp Dermatol 13:755–763CrossRefPubMedGoogle Scholar
  51. 51.
    Karsli N, Akcali C, Ozgoztasi O, Kirtak N, Inaloz S (2014) Role of oxidative stress in the pathogenesis of vitiligo with special emphasis on the antioxidant action of narrowband ultraviolet B phototherapy. J Int Med Res 42:799–805CrossRefPubMedGoogle Scholar
  52. 52.
    Rana S, Rogers LJ, Halliday GM (2011) Systemic low-dose UVB inhibits CD8 T cells and skin inflammation by alternative and novel mechanisms. Am J Pathol 178:2783–2791CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Park KK, Liao W, Murase JE (2012) A review of monochromatic excimer light in vitiligo. Br J Dermatol 167:468–478CrossRefPubMedGoogle Scholar
  54. 54.
    Sun Y, Wu Y, Xiao B, Li L, Li L, Chen HD, Gao XH (2015) Treatment of 308-nm excimer laser on vitiligo: a systemic review of randomized controlled trials. J Dermatolog Treat 26:347–353CrossRefPubMedGoogle Scholar
  55. 55.
    Bansal S, Sahoo B, Garg V (2013) Psoralen-narrowband UVB phototherapy for the treatment of vitiligo in comparison to narrowband UVB alone. Photodermatol Photoimmunol Photomed 29:311–317CrossRefPubMedGoogle Scholar
  56. 56.
    Dell’Anna ML, Mastrofrancesco A, Sala R, Venturini M, Ottaviani M, Vidolin AP, Leone G, Calzavara PG, Westerhof W, Picardo M (2007) Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol 32:631–636CrossRefPubMedGoogle Scholar
  57. 57.
    Lu L, Wang S, Fu L, Liu D, Zhu Y, Xu A (2015) Bilobalide protection of normal human melanocytes from hydrogen peroxide-induced oxidative damage via promotion of antioxidase expression and inhibition of endoplasmic reticulum stress. Clin Exp Dermatol. [Epub ahead of print] PMID: 26178968Google Scholar
  58. 58.
    Parsad D, Pandhi R, Juneja A (2003) Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol 28:285–287CrossRefPubMedGoogle Scholar
  59. 59.
    Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW (2013) The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol 149:68–73CrossRefPubMedGoogle Scholar
  60. 60.
    Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M (2015) Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol 151:42–50CrossRefPubMedGoogle Scholar
  61. 61.
    Rath N, Kar HK, Sabhnani S (2008) An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad/narrow band UVB phototherapy in progressive vitiligo. Indian J Dermatol Venereol Leprol 74:357–360CrossRefPubMedGoogle Scholar
  62. 62.
    Speeckaert R, Speeckaert MM, van Geel N (2015) Why treatments do(n’t) work in vitiligo: an autoinflammatory perspective. Autoimmun Rev 14:332–340CrossRefPubMedGoogle Scholar
  63. 63.
    Gokhale BB (1979) Cyclophosphamide and vitiligo. Int J Dermatol 18:92PubMedGoogle Scholar
  64. 64.
    Gupta AK, Ellis CN, Nickoloff BJ, Goldfarb MT, Ho VC, Rocher LL, Griffiths CE, Cooper KD, Voorhees JJ (1990) Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 126:339–350CrossRefPubMedGoogle Scholar
  65. 65.
    Radmanesh M, Saedi K (2006) The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat 17:151–153CrossRefPubMedGoogle Scholar
  66. 66.
    Singh H, Kumaran MS, Bains A, Parsad D (2015) A randomized comparative study of oral corticosteroid minipulse and low-dose oral methotrexate in the treatment of unstable vitiligo. Dermatology 231:286–290CrossRefPubMedGoogle Scholar
  67. 67.
    Rigopoulos D, Gregoriou S, Larios G, Moustou E, Belayeva-Karatza E, Kalogeromitros D (2007) Etanercept in the treatment of vitiligo. Dermatology 215:84–85CrossRefPubMedGoogle Scholar
  68. 68.
    Webb KC, Tung R, Winterfield LS, Gottlieb AB, Eby JM, Henning SW, Le Poole IC (2015) Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. Br J Dermatol 173:641–650CrossRefPubMedGoogle Scholar
  69. 69.
    Ruiz-Argüelles A, García-Carrasco M, Jimenez-Brito G, Sánchez-Sosa S, Pérez-Romano B, Garcés-Eisele J, Camacho-Alarcón C, Reyes-Núñez V, Sandoval-Cruz M, Mendoza-Pinto C, López-Colombo A (2013) Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study. Clin Exp Immunol 174:229–236PubMedPubMedCentralGoogle Scholar
  70. 70.
    Craiglow BG, King BA (2015) Tofacitinib Citrate for the Treatment of Vitiligo: a Pathogenesis-Directed Therapy. JAMA Dermatol 151:1110–1112CrossRefPubMedGoogle Scholar
  71. 71.
    Craiglow BG, King BA (2014) Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 134:2988–2990CrossRefPubMedGoogle Scholar
  72. 72.
    Lee DY, Choi SC, Lee DY (2012) A proposal for the treatment guideline in segmental vitiligo. Int J Dermatol 51:1274–1275CrossRefPubMedGoogle Scholar
  73. 73.
    Parsad D, Gupta S, IADVL Dermatosurgery Task Force (2008) Standard guidelines of care for vitiligo surgery. Indian J Dermatol Venereol Leprol 74:37–45Google Scholar
  74. 74.
    Malakar S, Dhar S (1999) Treatment of stable and recalcitrant vitiligo by autologous miniature punch grafting: a prospective study of 1,000 patients. Dermatology 198:133–139CrossRefPubMedGoogle Scholar
  75. 75.
    Das SS, Pasricha JS (1992) Punch grafting as a treatment of residual lesions of vitiligo. Indian J Dermatol Venereol Leprol 58:315–319Google Scholar
  76. 76.
    Kovacs D, Abdel-Raouf H, Al-Khayyat M, Abdel-Azeem E, Hanna MR, Cota C, Picardo M, Anbar TS (2015) Vitiligo: characterization of melanocytes in repigmented skin after punch grafting. J Eur Acad Dermatol Venereol 29:581–590CrossRefPubMedGoogle Scholar
  77. 77.
    Wassef C, Lombardi A, Khokher S, Rao BK (2013) Vitiligo surgical, laser, and alternative therapies: a review and case series. J Drugs Dermatol 12:685–691PubMedGoogle Scholar
  78. 78.
    Babu A, Thappa DM, Jaisankar TJ (2008) Punch grafting versus suction blister epidermal grafting in the treatment of stable lip vitiligo. Dermatol Surg 34:166–178CrossRefPubMedGoogle Scholar
  79. 79.
    Olsson MJ, Juhlin L (2002) Long-term follow-up of leucoderma patients treated with transplants of autologous cultured melanocytes, ultrathin epidermal sheets and basal cell layer suspension. Br J Dermatol 147:893–904CrossRefPubMedGoogle Scholar
  80. 80.
    Mulekar SV, Isedeh P (2013) Surgical interventions for vitiligo: an evidence-based review. Br J Dermatol 169(Suppl 3):57–66CrossRefPubMedGoogle Scholar
  81. 81.
    Falabella R (2009) Vitiligo and the melanocyte reservoir. Indian J Dermatol 54:313–318CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Sacchidanand S, Thakur P, Purohit V, Sujaya SN (2013) Follicular unit extraction as a therapeutic option for vitiligo. J Cutan Aesthet Surg 6:229–231CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Dhar S, Banerjee R, Malakar R (2014) Vitiligo in Children. In: Lahiri K, Chatterjee M, Sarkar R (Hrsg) Pigmentary disorders: a comprehensive compendium. Jaypee Brothers Medical Publishers(P) Ltd, New Delhi, S 167–179Google Scholar
  84. 84.
    Rao J, Fitzpatrick RE (2004) Use of the Q-switched 755-nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. Dermatol Surg 30:1043–1045PubMedGoogle Scholar
  85. 85.
    Alghamdi KM, Kumar A (2011) Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol 25:749–757CrossRefPubMedGoogle Scholar
  86. 86.
    Radmanesh M (2000) Depigmentation of the normally pigmented patches in universal vitiligo patients by cryotherapy. J Eur Acad Dermatol Venereol 14:149–152CrossRefPubMedGoogle Scholar
  87. 87.
    Eleftheriadou V, Whitton ME, Gawkrodger DJ, Batchelor J, Corne J, Lamb B, Ersser S, Ravenscroft J, Thomas KS (2011) Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership. Br J Dermatol 164:530–536PubMedPubMedCentralGoogle Scholar
  88. 88.
    Papadopoulos L, Bor R, Legg C (1999) Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. Br J Med Psychol 72:385–396CrossRefPubMedGoogle Scholar
  89. 89.
    Boone B (2007) Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 17:55PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Stiftung zur Förderung der Hochschulmedizin in DresdenDresdenDeutschland
  2. 2.Klinik und Poliklinik für DermatologieUniversitätsklinikum Carl Gustav CarusDresdenDeutschland

Personalised recommendations